Michael Orth

List of Publications by Year
in descending order

36 papers	1,150 citations	516710 16 h-index	526287 27 g-index
36 all docs	36 docs citations	36 times ranked	1993 citing authors

#	Article	IF	Citations
1	Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. Biomedicines, 2022, 10, 738.	3.2	8
2	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiation Oncology, 2022, 17, 79.	2.7	3
3	Serial TSPO and FET PET monitoring in experimental orthotopic glioblastoma and the impact of inflammation and astrogliosis related to the inoculation process. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	0
4	Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. Frontiers in Oncology, 2021, 11, 612354.	2.8	12
5	In vitro evaluation of simulated stereotactic radiotherapy for wet age-related macular degeneration on three different cell lines. Scientific Reports, 2021, 11, 8068.	3.3	1
6	Tumor-Specific Delivery of 5-Fluorouracilâ€“Incorporated Epidermal Growth Factor Receptorâ€“Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology, 2021, 161, 996-1010.e1.	1.3	20
7	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. Frontiers in Oncology, 2021, 11, 774017.	2.8	10
8	Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma. Cell Death and Disease, 2021, 12, 1162.	6.3	23
9	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology, 2020, 15, 5.	2.7	28
10	Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. Radiation Oncology, 2020, 15, 19.	2.7	8
11	Preclinical evaluation of F-18-PSMA PET in glioblastoma as a potential theranostic approach. , 2020, 59, .		0
12	PO-0999: Deciphering the tumor microenviroment based on PD-L1 expression and CD8 + TILs density in LA-NSCLC. Radiotherapy and Oncology, 2020, 152, S533.	0.6	0
13	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	2.7	285
14	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
15	PO-0780 Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy. Radiotherapy and Oncology, 2019, 133, S403.	0.6	0
16	Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy. Annals of Oncology, 2019, 30, ii11.	1.2	0
17	Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. Journal of Nuclear Medicine, 2019, 60, 1240-1246.	5.0	35
18	Duktales Adenokarzinom des Pankreas: biologische Merkmale, Stand der Dinge und Ausblick auf multimodale BehandlungsansÃtze der Zukunft. Karger Kompass Onkologie, 2019, 6, 196-208.	0.0	0

#	Article	IF	Citations
19	Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. OncoImmunology, 2019, 8, e1523097.	4.6	91
20	GSK3Î±/Î²: A Novel Therapeutic Target for Neuroendocrine Tumors. Neuroendocrinology, 2018, 106, 335-351.	2.5	10
21	OC-0488: Prognostic biomarkers and targets for personalization of radiotherapy of HNSCC: CD44v6. Radiotherapy and Oncology, 2018, 127, S251.	0.6	0
22	Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2. Oncogene, 2018, 37, 52-62.	5.9	31
23	OC-0220: Exploiting novel combined-modality approaches for treatment of highly aggressive pancreas carcinomas. Radiotherapy and Oncology, 2017, 123, S110.	0.6	1
24	Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Cancer Letters, 2017, 386, 87-99.	7.2	21
25	The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PLoS ONE, 2017, 12, e0178375.	2.5	10
26	A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget, 2016, 7, 43199-43219.	1.8	24
27	OC-0441: Genomic amplification of FancA in HNSCC: mechanisms of radioresistance and clinical relevance. Radiotherapy and Oncology, 2016, 119, S205-S206.	0.6	0
28	A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers. Oncotarget, 2016, 7, 7080-7095.	1.8	35
29	HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Letters, 2015, 365, 211-222.	7.2	40
30	A Human Bone Marrow Failure Syndrome Caused By a Homozygous Mutation in MYSM1. Blood, 2015, 126, 1204-1204.	1.4	1
31	Current concepts in clinical radiation oncology. Radiation and Environmental Biophysics, 2014, 53, 1-29.	1.4	143
32	OC-0482: Paclitaxel at lower nanomolar concentrations sensitizes tumor cells to irradiation by inducing aneuploidy. Radiotherapy and Oncology, 2014, 111, S189.	0.6	0
33	Dying cell clearance and its impact on the outcome of tumor radiotherapy. Frontiers in Oncology, 2012, 2, 116.	2.8	152
34	CDC-48/p97 Coordinates CDT-1 Degradation with GINS Chromatin Dissociation to Ensure Faithful DNA Replication. Molecular Cell, 2011, 44, 85-96.	9.7	88
35	Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO Journal, 2011, 30, 2868-2880.	7.8	34
36	NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins. Journal of Medicinal Chemistry, 2008, 51, 5035-5042.	6.4	12